Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. Participants of the "Conference on Medical and Surgical Treatment of Pituitary Adenomas" (Zürich, 5th October, 1991).

× No keyword cloud information.

22 in total

1. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients.

Authors: D A Ross; C B Wilson
Journal: J Neurosurg Date: 1988-06 Impact factor: 5.115

2. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status.

Authors: J C Reubi; A M Landolt
Journal: J Clin Endocrinol Metab Date: 1989-04 Impact factor: 5.958

3. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly.

Authors: J P Tauber; T Babin; M T Tauber; F Vigoni; A Bonafe; M Ducasse; A G Harris; F Bayard
Journal: J Clin Endocrinol Metab Date: 1989-05 Impact factor: 5.958

4. Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients.

Authors: P G Chiodini; A Liuzzi; L Botalla; G Oppizzi; E E Müller; F Silvestrini
Journal: J Clin Endocrinol Metab Date: 1975-04 Impact factor: 5.958

5. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.

Authors: S W Lamberts; R Oosterom; M Neufeld; E del Pozo
Journal: J Clin Endocrinol Metab Date: 1985-06 Impact factor: 5.958

6. Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH.

Authors: W H Daughaday; R H Starkey; S Saltman; J R Gavin; B Mills-Dunlap; E Heath-Monnig
Journal: J Clin Endocrinol Metab Date: 1987-10 Impact factor: 5.958

7. Rapid improvement in visual field defects following bromocriptine treatment of patients with non-functioning pituitary adenomas.

Authors: M C D'Emden; L C Harrison
Journal: Clin Endocrinol (Oxf) Date: 1986-12 Impact factor: 3.478

8. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.

Authors: G Plewe; J Beyer; U Krause; M Neufeld; E del Pozo
Journal: Lancet Date: 1984-10-06 Impact factor: 79.321

9. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).

Authors: G Faglia; N Bazzoni; A Spada; M Arosio; B Ambrosi; F Spinelli; R Sara; C Bonino; F Lunghi
Journal: J Clin Endocrinol Metab Date: 1991-10 Impact factor: 5.958

Review 4. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

Authors: J C Gillis; S Noble; K L Goa
Journal: Drugs Date: 1997-04 Impact factor: 9.546

4 in total

Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. Participants of the "Conference on Medical and Surgical Treatment of Pituitary Adenomas" (Zürich, 5th October, 1991).